Skip to main content
Fig. 3 | BMC Medicine

Fig. 3

From: Neoadjuvant trials in early breast cancer: pathological response at surgery and correlation to longer term outcomes – what does it all mean?

Fig. 3

Percentage of patients achieving pathological complete response (a) and HRs for overall survival (b), by subgroup.Information about clinical tumour stage available for 11 869 patients, about clinical nodal status for 11 807 patients, about histological type for 10,263 patients, about tumour grade for 8035 patients, and about clinical subtype for 5694 patients. ypT0/isypN0 definition of pathological complete response used. No multiplicity adjustment was made. HR hazard ratio, CI confidence interval, HER2 human epidermal growth factor receptor 2. (Reproduced with permission from The Lancet, Cortazar et al. [5]: License Number 3666940645625)

Back to article page